Olaparib inhibits oxLDL-mediated NLRP3 inflammasomes activity.

Abstract

THP-1 monocytic cells were exposed to oxLDL, the PARP inhibitor olaparib (Olapa), or the NLRP3 inhibitor MCC950 (MCC), individually or in combination as indicated. Proteins in cell lysates were detected with anti-NLRP3, anti-ASC, and anti-pro-caspase-1 (pro-CASP1) antibodies, as indicated. The band densities, relative to vinculin (loading control) were quantified using ImageJ (NIH, Bethesda, MD). N = 4/group, * P#P<0.05 vs oxLDL only, one-way ANOVA, Newman-Keuls test.</p